Autopsy report · NCT05828589

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

“This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years before it stopped.
• 51 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

BeOne Medicines

Sponsor type

Industry

Conditions

Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Relapsed Follicular Lymphoma; Relapsed Marginal Zone Lymphoma

Interventions

BGB-21447

Participants

51

Sites

28

Countries

Australia, China, New Zealand, United States

Trials that died the same way

• A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
  “This decision is due to a company business decision with a strategy change on the BGB-R046 development in Advanced or Metastatic Solid Tumors.” (80% match in meaning)
• Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
  “Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns.” (59% match in meaning)
• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (58% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (58% match in meaning)
• The KHENERGYC Study
  “Strategic company decision - not related to safety concerns” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.